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Research Question: Conflicting data exists on the utility of mitochondrial DNA 













Here, we determined whether blastocysts with highly elevated mitochondrial DNA 
(mtDNA) levels can result in healthy pregnancies and births, and whether 
mitochondrial functional output might be a readout of cell stress in the embryo.  
 
Design: We determined mtDNA levels in 109 blastocysts used in clinical transfers 
into 100 patients, noting their clinical outcomes. In a separate set of embryos, we 
quantified mitochondrial function in a model of embryo stress, aneuploidy. 
Measurement of mtDNA levels made use of surplus material from the preimplantation 
genetic testing (PGT-A) process, and followed recently proposed unifying guidelines 
for mtDNA quantitation.  
 
Results: Unusually high mtDNA levels did not preclude blastocyst implantation and 
healthy births. Analysis of 109 blastocysts showed a statistically insignificant 
(P=0.231) difference between mtDNA levels in implanted (n=55) versus non-
implanted (n=54) blastocysts. We could not detect obvious differences in degree of 
mitochondrial functional output in a model of embryo stress. 
 
Conclusions: Measurement of mtDNA copy number might not provide any 
advantage to embryo prioritization and could lead to de-selection of blastocysts that 
would result in healthy pregnancies and births. Furthermore, the quantitation of 
mitochondrial functional output in a model of cellular stress might suggest that 













blastocyst viability. Any suggested link between mtDNA levels, mitochondria, or their 




Blastocysts containing highly elevated mtDNA levels can result in healthy 
pregnancies and births when selected for clinical transfer.   
 
KEYWORDS  
mitochondria, mtDNA, implantation, biomarker, blastocyst 
 
INTRODUCTION 
In vitro fertilization (IVF) has made it possible for many patients experiencing infertility 
to achieve pregnancy, but in spite of tremendous advances since its inception 40 
years ago, the process remains relatively inefficient (Niederberger et al., 2018). On 
average, only 37.1% of embryo transfers result in implantation at IVF programs 
based in the USA according to the Society for Assisted Reproductive Technology 
(SART). Efforts to increase the likelihood of implantation and establishment of a 
healthy pregnancy include the identification of a biomarker predictive of viability. An 
ideal biomarker is a parameter that shows variability in the general embryo 
population that, when measured, provides a significant degree of predictive power of 
an embryo’s chances to implant. Embryo metabolism has long been linked to viability 













metabolism to rank embryos within a patient’s cohort could effectively increase the 
chances of success with fewest possible attempts (Gardner et al., 2011).  
Mitochondria not only contribute significantly to the energy production for 
many cellular processes in the form of adenosine triphosphate (ATP), they also 
regulate apoptosis, calcium signalling, management of reactive oxygen species, 
pyruvate and citric acid cycle, heme and steroid synthesis, and hormonal signalling 
(Harvey, 2019). Each human cell may contain a wide range in the number of 
mitochondrial organelles and each mitochondrion can contain numerous copies of 
mitochondrial DNA (mtDNA) (Lima et al., 2018). MtDNA is a circular molecule 
comprising 16.6 kb encoding 37 genes necessary for mitochondrial function. Due to 
its multicopy nature, mtDNA has typically been quantified on a per cell basis. That 
value is an assessment of ‘mtDNA levels’ that can be compared between any 
discreet populations of cells, such as individual human embryos or cellular biopsies 
thereof. It is nevertheless important to note that the value of mtDNA levels does not 
necessarily reflect the actual number of mitochondria. 
 Four recent studies stemming from two separate groups reported that 
trophectoderm (TE) biopsies from blastocysts that successfully implanted showed 
lower mtDNA levels on average, compared to blastocysts that did not implant after 
transfer (Diez-Juan et al., 2015; Fragouli et al., 2017; Fragouli et al., 2015; 
Ravichandran et al., 2017). Interestingly, those studies also described a threshold of 
mtDNA levels that, when surpassed, always resulted in implantation failure. The 
authors proposed that elevated mtDNA levels could be a feature of blastocysts 













would promote mtDNA replication in a concerted effort to increase rates of cellular 
respiration and ATP production to meet increased energetic demands. Fragouli and 
colleagues suggested coupling this model to the the Quiet Embryo Hypothesis, which 
predicts that under ideal conditions an embryo experiences a calm metabolism 
(Leese, 2002). However, all data for the Quiet Embryo Hypothesis were collected 
under conditions of oxidative stress (20% oxygen), and consequently this hypothesis 
has been shown to be invalid for embryos cultured in physiological oxygen 
concentrations (5%) (Gardner and Wale, 2013). 
The interest generated by such reports encouraged numerous groups to 
explore the matter of mtDNA levels in their respective clinics. An independent study 
found no statistically significant correlation between mtDNA levels and implantation 
potential in blastocysts (Victor et al., 2017). Those findings were also confirmed in a 
subsequent report analysing double embryo transfers (Treff et al., 2017), which 
revealed that blastocysts with lower mtDNA levels were just as likely to implant than 
their paired counterparts with higher mtDNA levels. Subsequently, a further two 
published studies failed to observe any statistically significant predictive power of 
mtDNA levels in regard to implantation in human blastocysts (Klimczak et al., 2018; 
Shang et al., 2018). 
Several opinions have been expressed attempting to explain the disparate 
results (Barnes et al., 2017; Humaidan et al., 2018; Viotti et al., 2017; Wells et al., 
2017). Recently, a Views and Reviews piece focused on the possibility that technical 
variability in methods of mtDNA quantitation might be the reason for discrepancies, 













2017). Those were: I) avoiding the use of Next Generation Sequencing platforms with 
low coverage of the mtDNA genome, II) using polymerase chain reaction (qPCR) 
targeting a mitochondrial region and a multicopy nuclear region for correct 
normalization to prevent allele-drop-out issues during analysis, and III) excluding 
samples of DNA material that may have degraded due to long-term frozen storage 
(Wells, 2017). 
Consequently, we adhered to the proposed guidelines of mtDNA quantitation 
when analysing mtDNA levels in a set of blastocysts used for transfer. In doing so, it 
was possible to test whether technical variations in mtDNA quantitation were 
responsible for conflicting reports regarding the usefulness of mtDNA levels as a 
biomarker for implantation. The clinical outcomes of all tested blastocysts through 
implantation, pregnancy, and birth were followed, and further it was established 
whether mitochondrial function in blastocysts correlated with cellular stress. 
MATERIALS AND METHODS 
Patients and Embryos 
Embryos derived from patients seeking infertility treatment at a private IVF center 
were generated by intracytoplasmic sperm injection (ICSI) and cultured to the 
blastocyst stage under 5% oxygen, using standard techniques, as previously 
described (Victor et al., 2017). Blastocysts were evaluated with the Gardner system 
(Gardner and Schoolcraft, 1999) and subjected to a 5-10 cell TE biopsy and vitrified 
until further use. Preimplantation genetic testing for aneuploidy (PGT-A) was 
performed in-house utilizing the VeriSeq kit (Illumina) following the manufacturer’s 













classified as euploid were selected for transfer, and the presence of a gestational sac 
observed by endovaginal ultrasound at 3-5 weeks after transfer was considered 
evidence of implantation. The imaging experiments were performed on 
supernumerary embryos donated to research by informed consent.  
This study was approved by the Zouves Foundation IRB (OHRP IRB00011505, 
Protocol #0003). 
  
mtDNA Quantitation  
During the PGT-A process, isolated DNA from individual TE biopsies was multiplied 
by whole genome amplification (WGA) and subsequently sequenced. Surplus WGA 
material from each sample was used to determine mtDNA levels by qPCR on a 
QuantStudio 3 instrument (Thermo Fisher). A 1:10 dilution of WGA product in water 
was vortexed for 30-60 seconds followed by heating to 95°C for 10 minutes in order 
to inactivate any residual WGA polymerase activity. Two microliters were used in a 
Taqman Fast Advanced Master Mix reaction (Thermo Fisher), with each reaction run 
in technical triplicates. Each reaction plate contained an equilibrator sample, used for 
global normalization across the entire experiment. 
A mitochondrial locus was quantified with a commercially available Taqman 
assay for the mitochondrial ND6 gene (Hs02596879_g1), which had been previously 
thoroughly validated in the context of blastocyst TE biopsies (Treff et al., 2017; Victor 
et al., 2017). A multicopy nuclear DNA sequence was quantified using a previously 
described, custom-made Taqman assay targeting the Ya5 subfamily of Alu repeats 













the human genome. Details for the Alu-Ya5 assay were: forward primer 
gaccatcccggctaaaacg, reverse primer cgggttcacgccattctc, and probe 
ccccgtctctactaaa. 
ND6 and Alu-Ya5 assays yielded a cycle threshold (Ct) value, which was used 
to determine the normalized mtDNA level for any sample as follows:  
2-(CtND6-CtAlu). Hence, the final value for mtDNA level is a ‘per cell’ measure. 
 
Fluorescent Staining of Whole Blastocysts  
Supernumerary thawed blastocysts were allowed to equilibrate in an incubator for 24 
h, after which media was replaced with fresh media containing 250 nM of MitoTracker 
Deep Red FM (Thermo Fisher #M22426). After 30 min in the incubator, blastocysts 
were processed for immunofluorescence following a previously described protocol 
(Victor et al., 2018), using the primary antibodies (abs) mouse anti-human GATA3 
monoclonal ab (Thermo Fisher #MA1-028) and rabbit anti-human OCT4A 
monoclonal ab (Cell Signaling #2890) followed by the secondary abs goat anti-rabbit 
IgG AlexaFluor488 (Thermo Fisher A11008) and goat anti-mouse IgG AlexaFluor546 
(Thermo Fisher A11030). Subsequently, blastocysts were exposed to nuclear stain 
(Hoechst 33342, Thermo Fisher H3570) and imaged.  
 
Imaging and Computational Quantitation of Mitochondrial Function  
Stained blastocysts were placed in glass bottom dishes (MatTek P35G-1.5-20-C) in 
small drops of stain buffer overlaid with mineral oil (Sigma M5904), and imaged with 













uploaded into the software package Imaris 8.4.1 (Bitplane). Fluorescent channels 
were individually quantified in a blinded fashion computationally for each blastocyst 




Analysis and graph preparation was done in Prism 6 (GraphPad). In Fig. 2A, 
differences between groups were assessed by unpaired, two-tailed Student’s t test 
with Welch’s correction. In Fig. 3C, differences were assessed by one-way ANOVA. 
For all analyses, significance was defined when P < 0.05. 
 
RESULTS 
Quantifying mtDNA in Blastocysts 
To conform to the recently suggested guidelines for mtDNA quantitation in TE 
biopsies of human embryos (Wells, 2017), we used qPCR on TE-derived surplus 
WGA material stored at -80C for less than 2 months without any freeze-thaw cycles. 
The qPCR targeted a region in the mtDNA sequence (ND6) and a multicopy region in 
the nuclear DNA (Alu-Ya5), using the latter as a reference to normalize for technical 
variability in the WGA run and number of cells in collected biopsy. To validate the 
assays, we performed 10-fold dilution series of a WGA sample from a TE biopsy of a 
euploid embryo to determine the following qPCR reaction efficiencies: 97.7% for ND6 














MtDNA Levels Have No Predictive Power Relating to Implantation  
Average levels of mtDNA were not statistically different between the set of euploid 
blastocysts that achieved implantation and those that did not (P=0.231).  
 (Fig. 2A). The majority of blastocysts had mtDNA levels within a range of substantial 
overlap between implanted and not implanted groups. Both groups also contained 
outliers that could be regarded as having elevated mtDNA levels. In the implanted 
group, there were three blastocysts with mtDNA levels just above one standard 
deviation of the mean, and two blastocysts with considerably higher mtDNA levels 
(together, those five blastocysts are labeled #1-5 in Figure 2A and Table 1).  
 
Blastocysts With Elevated mtDNA Levels Can Result In Healthy Pregnancies 
and Births  
 
The transfers of blastocysts #1-5 resulted in normal pregnancies and live births. 
Blastocyst #1 was particularly noteworthy for its disproportionately high mtDNA levels 
(~4x the group average). It was also the blastocyst with highest mtDNA levels within 
its respective patient cohort (Figure 1B), which means that it would not have been 
chosen for transfer had mtDNA levels been used for de-deselection of embryos for 
transfer. It had good overall morphology at the time of TE biopsy (4AA) and after a 
vitrification-thaw cycle, immediately before transfer (5AA) (Figure 1C).  
All five babies resulting from this group of blastocysts with elevated mtDNA 













screened conditions by blood test, including various metabolic disorders (for a list of 
the 63 tested conditions see Table 2).  
 
Cellular Stress Associated with Aneuploidy Does Not Necessarily Lead To 
Increased Mitochondrial Activity in Blastocysts 
We investigated the biological mechanism proposed by other groups explaining why 
elevated mtDNA levels and implantation failure might be correlated. It postulated that 
mtDNA levels might increase as part of a compensatory mechanism employed by 
embryonic cells when experiencing energetic stress (Diez-Juan et al., 2015; Fragouli 
et al., 2015). MtDNA levels might therefore be a corollary of a larger program that 
increases mitochondrial organelle number, as well as mitochondrial functional output. 
Accordingly, mitochondrial activity should be a more direct readout of the proposed 
embryo stress, and could be a potentially better biomarker of viability.  
 To test this possibility, we exposed blastocysts to MitoTracker Deep Red 
(MTDR) (Fig. 3A and B, Video 1). This fluorescent dye is associated with active 
mitochondria and its accumulation is dependent upon inner mitochondrial membrane 
potential, which increases with cellular respiration. Quantitation of MTDR fluorescent 
signal is therefore an indirect indicator of mitochondrial activity (Hallap et al., 2005; 
Kanno et al., 2016; Kodiha et al., 2015). In addition, on the same blastocysts we 
performed immunofluorescence with antibodies targeting a TE marker (GATA3) and 
an ICM marker (OCT4) to be able to differentiate mitochondrial function in the two 













To model the impact of cell stress, we analyzed mitochondrial function in 
blastocysts that had different classifications after PGT-A testing. Aneuploidy is known 
to be associated with global increases in cellular trauma including metabolic, 
proteotoxic, replicative, and mitotic cell stress (Sheltzer, 2013; Stingele et al., 2012; 
Zhu et al., 2018). Accordingly, euploid blastocysts were expected to exhibit the least 
cellular stress, followed by mosaic blastocysts, then by blastocysts with aneuploidy 
affecting a single chromosome, and lastly by blastocysts with aneuploidy affecting 
multiple chromosomes, which would have the most cellular aberrations.  
 On average, mitochondrial activity per cell in the TE was considerably higher 
than in the ICM, in agreement with previously reported data (Van Blerkom, 2011). 
Nonetheless, we noted no statistically significant difference regarding mitochondrial 
activity per cell when comparing the different blastocysts groups (P=0.958 in the TE, 
P=0.946 in the ICM) (Figure 3C). 
DISCUSSION 
Biomarkers predictive of implantation are urgently needed to reduce time to 
pregnancy and to help establish healthy pregnancies in IVF (Ferrick et al., 2019; 
Gardner et al., 2015). Here we tested whether mtDNA levels possessed prognostic 
qualities regarding blastocyst transfer outcome in our clinic, abiding to suggested 
guidelines of mtDNA quantitation (Wells, 2017). We found no association between 
mtDNA levels and blastocyst viability, and we report for the first time that blastocysts 
with extremely high mtDNA copy number are consistent with viable implantation, 
normal pregnancy, and birth. Using a unified system of mtDNA quantitation, we 













discrepancies between our findings and those previously describing a prognostic 
value of mtDNA levels in blastocysts (Diez-Juan et al., 2015; Fragouli et al., 2017; 
Fragouli et al., 2015; Ravichandran et al., 2017; Victor et al., 2017). 
 One scenario that reconciles the conflicting reports is a laboratory-selective 
association between mtDNA levels and implantation. In fact, it has been reported that 
the incidence of blastocyst with elevated mtDNA levels varies widely amongst IVF 
centers (Ravichandran et al., 2017). Out of 35 clinics participating in that study, 
roughly half did not produce an appreciable percentage of blastocysts with high 
mtDNA levels, although it must be noted that for some centers the analyzed sample 
size was small. In the remaining centers, incidences of blastocysts with elevated 
mtDNA levels ranged from 1% to 27%. Of blastocysts analyzed in this study, three 
out of 109 (2.8%) could be considered as containing highly elevated mtDNA levels 
(two implanted, one did not), and yet mtDNA quantitation was not valuable in 
predicting implantation in our setting. 
 One can only speculate why those three embryos contained highly elevated 
mtDNA levels. Under normal circumstances, no new mtDNA replication occurs 
between zygote and blastocyst stage, such that the initial set mtDNA molecules 
becomes split between dividing cells and progressively diluted amongst cells of the 
developing embryo (Cecchino et al., 2018; St John et al., 2010). Therefore, if a cell 
fails to undergo one or more cell divisions, it will tend to retain its mtDNA content. It is 
possible that for the three blastocysts yielding highly elevated mtDNA levels the 
collected biopsy happened to contain a region of the TE that had undergone fewer 













regions. The blastocyst with the highest mtDNA levels, which contained fourfold the 
content compared to the group average, could be explained if the sampled TE cells 
had skipped two cell divisions compared to other TE regions of that blastocyst. What 
might have caused attenuated cell division in that part of the TE is another question, 
although to the best of our knowledge there is no clear evidence suggesting that all 
TE regions proliferate at equal rates under normal conditions. For example, TE cells 
adjacent to the section of the zona pellucida making contact with the dish during 
culture might experience distinct cell proliferation dynamics.  
Alternatively, it has been shown in several mammalian species that once the 
blastocyst stage is reached, replication of mtDNA begins specifically in the TE while 
the ICM continues to reduce its mtDNA copy number (St John et al., 2010; Van 
Blerkom, 2011). Whether mtDNA replication occurs uniformly across TE cells or in a 
localized fashion is not well studied, and might be affected by the cell cycle stage of 
each individual TE cell. A spurt of mtDNA replication in a sampled region would result 
in high mtDNA levels being quantified for the entire corresponding embryo. 
MtDNA levels have been proposed to be a surrogate measure of mitochondrial 
function, which was presumed to increase in blastocysts experiencing stress (Diez-
Juan et al., 2015; Fragouli et al., 2015). Nonetheless, a direct relationship between 
mtDNA levels and mitochondrial function in the blastocysts has not been documented 
(Van Blerkom, 2004). To shed light on this matter, mitochondrial function in 
blastocysts euploid and aneuploid blastocysts were analysed. Even though the data 
suggest that ploidy does not affect mitochondrial function in blastocysts, it is possible 













mitochondrial activation in blastocysts, such as for example changes in oxygen 
concentration (Gardner and Harvey, 2015). The state of aneuploidy (the model tested 
here) can elicit increases in various types of cell stress (metabolic, proteotoxic, 
replication, and mitotic) (Zhu et al., 2018), but it is possible that only a specific sub-
type of energetic stress prompts mitochondrial activation, and consequently shifts in 
mtDNA levels. What is more, the trigger might depend on a specific threshold of that 
stress factor. Future studies need to test whether lab-induced variance of parameters 
including oxygen concentration, medium composition, pH, and/or temperature affect 
mitochondrial function and/or content in human embryos. This in turn could help to 
explain the observation that different centers generate vastly different incidences of 
blastocysts with highly elevated mtDNA levels (Ravichandran et al., 2017), a 
phenomenon for which the underlying biological basis remains unknown. We surmise 
that for the time being, the suggested rationale linking increased mtDNA levels to 
stress remains purely speculative.  
CONCLUSIONS 
 
Based upon the results of this study that conforms to proposed guidelines of mtDNA 
quantitation, mtDNA levels were not predictive of implantation potential. Importantly, 
blastocysts with disproportionally elevated mtDNA levels resulted in healthy 
pregnancies and births. The functional output of mitochondria is not significantly 
elevated in a model of embryo stress, refuting the previously suggested model that 













biomarker of implantation. Future studies are needed to investigate in which cases 
mtDNA quantitation may be useful. 
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Supplemental Video 1. Video of confocal microscopy-imaged embryo after 
immunofluorescence staining, displaying quantitation method. This 
representative sample was classified as euploid with PGT-A. Note that the image 
analysis software detects the concrete number (count) of nuclei (blue), ICM cells 
(white), TE cells (red). MTDR signal (green) is quantified as fluorescent signal 
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Figure 1.  
Technical validation of qPCR assays used in this study to quantify mtDNA 
levels per cell.  
















Figure 2.  
MtDNA levels are not predictive of implantation in the analyzed cohort.  
 
(A) Comparison of mtDNA levels between blastocysts that implanted 
and those that did not. Each data point represents the mtDNA levels 
of one blastocyst.  
 
(B) Plotted mtDNA levels of all euploid blastocysts from patient who 
generated blastocyst #1 in (A). 
 
(C) Images of blastocyst #1 in (A), immediately before collection of a TE 
biopsy and vitrification (left image), and before transfer (right 































Figure 3.  
Quantitation of mitochondrial activity in blastocysts. 
 
(A) High resolution image of TE cells after exposure to Hoechst nuclear 
stain and MTDR, displaying fluorescent MTDR signal in 
characteristic punctate distribution around nuclei. Scale bar = 10μm 
  
(B) Left column shows representative immunofluorescent images of a 
whole hatching blastocyst. Right column shows method of 
computational detection and quantitation. Note that the image 
analysis software detects the concrete number (count) of nuclei, 
ICM cells, and TE cells. The software generates a ‘mask’ of the 
MTDR signal, and quantifies the fluorescence within. The yellow 
number at the bottom right corner of panels indicates the computed 
value for the corresponding image. Scale bar = 30μm 
 
(C) Scatter dot plots depicting quantitation of MTDR fluorescence 
(readout of mitochondrial function) in blastocysts. Each symbol 
represents one blastocyst. Lines indicate mean with standard 
deviation. Sample size of each blastocyst group is n=4 Euploids, 
n=4 Mosaics, n=8 Single Aneuploids (aneuploidy affecting a single 
chromosome), n=7 Multiple Aneuploids (with aneuploidy affecting 


















































#1 4AA D5 Normal 0.02899 4.70x Yes Yes 
#2 5BB D6 Normal 0.01635 2.65x Yes Yes 
#3 5BB D6 Normal 0.01291 2.09x Yes Yes 
#4 3AB D5 Normal 0.01208 1.96x Yes Yes 


















Table 2. Conditions tested in newborns resulting from transfers of blastocysts 






Argininosuccinic Aciduria (ASA) 
Benign Hyperphenylalaninemia (H-PHE) 
Biopterin Defect in Cofactor Biosynthesis (BIOPT-BS) 
Biopterin Defect in Cofactor Regeneration (BIOPT-REG) 
Carbamoyl Phosphate Synthetase I Deficiency (CPS) 
Citrullinemia, Type I (CIT) 
Citrullinemia, Type II (CIT II) 
Classic Phenylketonuria (PKU) 
Homocystinuria (HCY) 
Hypermethioninemia (MET) 
Hyperornithine with Gyrate Deficiency (Hyper ORN) 
Maple Syrup Urine Disease (MSUD) 
Ornithine Transcarbamylase Deficiency (OTC) 
Prolinemia (PRO) 
Tyrosinemia, Type I (TYR I) 
Tyrosinemia, Type II (TYR II) 
Tyrosinemia, Type III (TYR III) 
Endocrine 
Disorders 
Congenital Adrenal Hyperplasia (CAH) 
Primary Congenital Hypothyroidism (CH) 
Fatty Acid 
Oxidation Disorders 
Carnitine Acylcarnitine Translocase Deficiency (CACT) 
Carnitine Palmitoyltransferase I Deficiency (CPT-IA) 
Carnitine Palmitoyltransferase Type II Deficiency (CPT-II) 
Carnitine Uptake Defect (CUD) 
Glutaric Acidemia, Type II (GA-2) 
Long-Chain L-3 Hydroxyacyl-CoA Dehydrogenase Deficiency (LCHAD) 
Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD) 
Medium/Short-Chain L-3 Hydroxyacyl-CoA Dehydrogenase Deficiency (M/SCHAD) 
Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD) 
Trifunctional Protein Deficiency (TFP) 
Very Long-Chain Acyl-CoA Dehydrogenase Deficiency (VLCAD) 
Hemoglobin 
Disorders 
Hemoglobinopathies (Var Hb) 
S, Beta-Thalassemia (Hb S/ßTh) 
S, C Disease (Hb S/C) 
Sickle Cell Anemia (Hb SS) 
Lysosomal Storage 
Disorders 




2-Methyl-3-Hydroxybutyric Acidemia (2M3HBA) 
2-Methylbutyrylglycinuria (2MBG) 
3-Hydroxy-3-Methylglutaric Aciduria (HMG) 
3-Methylcrotonyl-CoA Carboxylase Deficiency (3-MCC) 
3-Methylglutaconic Aciduria (3MGA) 
Beta-Ketothiolase Deficiency (BKT) 
Ethylmalonic Encephalopathy (EME) 
Glutaric Acidemia, Type I (GA-1) 
Holocarboxylase Synthetase Deficiency (MCD) 
Isobutyrylglycinuria (IBG) 













Malonic Acidemia (MAL) 
Methylmalonic Acidemia (Cobalamin Disorders) (Cbl A,B) 
Methylmalonic Acidemia (Methymalonyl-CoA Mutase Deficiency) (MUT) 
Methylmalonic Acidemia with Homocystinuria (Cbl C, D, F) 
Propionic Acidemia (PROP) 
Other Disorders Adrenoleukodystrophy (ALD) 
Biotinidase Deficiency (BIOT) 
Classic Galactosemia (GALT) 
Critical Congenital Heart Disease (CCHD) 
Cystic Fibrosis (CF) 
Formiminoglutamic Acidemia (FIGLU) 
Hearing loss (HEAR) 
Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome (HHH) 
Severe Combined Immunodeficiency (SCID) 
T-cell Related Lymphocyte Deficiencies 
 
 
 
 
 
